Discounted Cash Flow Rating

Strong Sell

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Strong Buy

Price to Earnings Rating

Buy

Analyst Rating

Sell

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Neutral

Standard Deviation

Sell

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Strong Buy

Wall Street Data Solutions Rating

Neutral

B

Celularity Inc. Class A Common Stock (CELU)

Pharmaceutical Preparations

https://www.celularity.com

Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases.

170 PARK AVE
FLORHAM PARK, NJ

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

07/19/2021

Market Cap

65,122,782

Shares Outstanding

193,780,000

Weighted SO

215,192,624

Total Employees

N/A

Upcoming Earnings

05/27/2024

Similar Tickers

IMMX --.--%

ZVSA --.--%

HEPA --.--%

AVRO --.--%

EFTR --.--%

CNSP --.--%

VECT --.--%

NAVB --.--%

Beta

0.4440

Last Div

0.0000

Range

1.59-7.97

Chg

0.0122

Avg Vol

17509

Mkt Cap

65122782

Exch

NASDAQ

Country

US

Phone

908 768 2170

DCF Diff

8.5654

DCF

-3.5454

Div Yield

0.0000

P/S

2.8599

EV Multiple

-1.7538

P/FV

1.2882

Div Yield %

0.0000

P/E

-0.2688

PEG

-0.0386

Payout

0.0000

Current Ratio

0.2941

Quick Ratio

0.2086

Cash Ratio

0.0034

DSO

194.2414

DIO

52.5829

Op Cycle

246.8242

DPO

129.2773

CCC

117.5469

Gross Margin

-0.7537

Op Margin

-8.4444

Pretax Margin

-8.6200

Net Margin

-8.6204

Eff Tax Rate

0.0033

ROA

-1.3642

ROE

-2.2737

ROCE

-2.5106

NI/EBT

1.0001

EBT/EBIT

1.0208

EBIT/Rev

-8.4444

Debt Ratio

0.4546

D/E

1.5971

LT Debt/Cap

0.3899

Total Debt/Cap

0.6150

Int Coverage

-63.7768

CF/Debt

-0.5914

Equity Multi

3.5129

Rec Turnover

1.8791

Pay Turnover

2.8234

Inv Turnover

6.9414

FA Turnover

0.2889

Asset Turnover

0.1583

OCF/Share

-2.1717

FCF/Share

-2.3990

Cash/Share

0.0127

OCF/Sales

-1.6989

FCF/OCF

1.1046

CF Coverage

-0.5914

ST Coverage

-0.9859

CapEx Coverage

-9.5566

Div&CapEx Cov

-9.5566

P/BV

1.2882

P/B

1.2882

P/S

2.8599

P/E

-0.2688

P/FCF

-1.5239

P/OCF

-1.3640

P/CF

-1.3640

PEG

-0.0386

P/S

2.8599

EV Multiple

-1.7538

P/FV

1.2882

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. May 30, 21:30 Celularity Receives Nasdaq Notice Regarding Form 10-Q GlobeNewswire Inc. Apr 25, 21:30 Celularity Receives Nasdaq Notice Regarding Non-Payment of Nasdaq Fees GlobeNewswire Inc. Oct 16, 21:15 Celularity Expands Advanced Biomaterial Product Commercial Portfolio with Acquisition of Rebound™ Product from Sequence LifeScience, Inc. Benzinga Oct 16, 21:15 Celularity Expands Advanced Biomaterial Product Commercial Portfolio with Acquisition of Rebound™ Product from Sequence LifeScience, Inc. GlobeNewswire Inc. Aug 23, 21:00 Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing GlobeNewswire Inc. Jan 18, 13:40 Celularity Releases CEO Letter to Shareholders GlobeNewswire Inc. Jan 04, 13:00 Celularity Confirms Commercialization Agreement with BioCellgraft for the Manufacture and Distribution of Advanced Biomaterial Products for Use in Oral Healthcare GlobeNewswire Inc. Nov 24, 13:15 Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing GlobeNewswire Inc. Nov 24, 13:15 Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing

Revenue Product Segmentation